Schrödinger, Inc. (SDGR) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

Event: Schrödinger presented at the KeyBanc Healthcare Virtual Forum on March 17, 2026. Management reiterated its mission to develop a computational platform to accelerate and improve drug and materials discovery, aiming to replace traditional trial-and-error experimental cycles. They noted platform changes over the past 6–12 months and emphasized reduced time and failure rates in molecule optimization. No financial results, guidance, transactions, or material corporate actions were disclosed.

Analysis

Schrödinger’s core asset is a physics-first computational stack whose second-order value is not just faster hit-finding but compression of the downstream experimental budget per validated lead. Expect partners to reallocate capex from brute-force HTS plates into higher-margin, bespoke CRO and custom-synthesis work for the smaller set of higher-confidence molecules — that shifts economics in favor of CROs that can scale bespoke capacity quickly and raises per-candidate revenue capture for Schrodinger via milestone/licensing terms.

Competitive dynamics favor firms with both validated predictive performance and defensible IP; pure-ML players face secular margin pressure if customers prefer physics models for explainability and regulatory defensibility. Cloud providers (AMZN/GOOG/MSFT) are an indirect lever: a successful scale-up increases high-precision compute demand (GPU/FP64 cycles) and creates a sticky revenue stream for hyperscalers, while GPU supply shocks or step-function increases in compute pricing would compress partner economics and slow adoption over 6–18 months.

Key risk vectors are reproducibility and partner concentration — a single high-profile failed program or a terminated pharma collaboration could force a re-rating within a quarter; conversely, 1–3 substantive collaboration announcements or an IND filing tied to platform-derived chemistry could re-rate the name by 30–60% over 6–18 months. The market appears to misprice the materials-science optionality and IP-licensing runway; position sizing should reflect binary event risk and a multi-year optionality payoff rather than near-term linear revenue growth.

Key Decisions for Investors

• Long SDGR equity with asymmetric downside protection: Buy SDGR shares and hedge with a 9–12 month 25–30% OTM put. Rationale: preserves upside to binary partnership/IND catalysts over 6–18 months while capping drawdown from an adverse collaboration outcome; target 2.5x upside if one large pharma collaboration advances or a materials licensing deal is announced.
• Defined-cost upside via options: Buy a 12–18 month SDGR call spread (buy nearer-term ATM call, sell 50–80% OTM call) to finance exposure to platform optionality. Rationale: limited capital outlay (~20–30% of outright calls) to capture 30–70% upside on successful catalysts; loss limited to premium paid.
• Relative-value pair: Long SDGR / Short EXAI or RXRX (6–18 month horizon). Rationale: favor physics-based modeling with multi-industry optionality (materials + pharma) over ML-first peers; expect 20–40% relative outperformance if Schrodinger continues closing diversified commercial deals. Stop-loss: 15% adverse move on pair.
• Indirect infrastructure play: Buy or overweight AMZN/GOOG/Microsoft for 12 months to capture increased cloud/GPU demand from platformized discovery. Rationale: if Schrodinger and peers scale, hyperscalers capture recurring compute revenues with lower execution risk; target total return 15–25% if compute utilization increases materially.